Life Science Intelligence

The  global electrosurgical devices market  is undergoing a profound transformation, driven by innovation in surgical techniques and the growing adoption of robotic surgery. The increasing integration of electrosurgical tools into robotic platforms is reshaping the competitive landscape and enhancing the precision of soft tissue surgeries. As the demand for less invasive surgeries rises, electrosurgical devices play a crucial role in this shift, providing surgeons with advanced tools for tissue cutting, coagulation, and ablation. This article delves into the current state of the electrosurgical devices market, focusing on key industry trends, major players, and emerging technologies that are driving growth in 2025. It also explores how the landscape is shifting, with companies like Medtronic, Johnson & Johnson MedTech, and Intuitive Surgical leading the charge in robotic-assisted surgeries. Overview of the Electrosurgical Devices Market in 2025 Electrosurgical devices, whi...

  The   transcatheter aortic valve replacement (TAVR) market   is undergoing significant evolution. As the demand for less invasive heart valve procedures continues to rise, the competitive landscape is rapidly shifting. Medtech giants like Medtronic and Edwards Lifesciences remain dominant, but innovation continues to play a crucial role in reshaping the future of the TAVR market. This article dives into the current state of the TAVR market, key industry players, and the forces driving growth, as well as recent industry moves such as Boston Scientific’s decision to exit the TAVR space. The TAVR Landscape in 2025 Since its U.S. approval in 2011, TAVR has transformed the treatment of severe aortic stenosis. Particularly beneficial for high-risk patients who are not candidates for open-heart surgery, TAVR has quickly become the standard procedure for aortic valve replacement in many countries. The procedure’s appeal lies in its less invasive nature, shorter recovery time, a...

  In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni secure over $17M in new funds, achieve regulatory clearances, appoint new executives, and much more on the road to  LSI Europe  ’25 in London (September 7–11). Adialante Received a $1.18M National Science Foundation SBIR Phase II award to advance the development of its compact, silent, and low-cost MRI technology. The funding brings Adialante’s total raised to nearly $3M as the team works to expand access to high-quality medical imaging worldwide. Asabys Partners Promoted Maite Malet and Isabel Jiménez Bernal to Principal in recognition of their leadership and impact across the firm’s healthcare investment strategy. Asabys continues to strengthen its position in health-tech and biopharma by advancing transformative technologies alongside top industry talent. Berkshire Biomedical Was awarded Phase I of a two-phase Fast-Track SBIR grant from the National Institutes of ...

Join moderator Amir Soltanianzadeh and Dr. Asif Ali from the American Heart Association as they explore how wearable technology is revolutionizing cardiac care and shaping its future. For more information watch this video:  https://www.lifesciencemarketresearch.com/videos/signature-series-the-future-of-wearables-in-cardiac-care-lsi-usa-25

  Join moderator Henry Peck along with speakers Josh DeFonzo (Mendaera, Inc.) and Andy McGibbon (Vitestro) as they explore how scaling robotics beyond specialized uses can address medical scarcity and rising healthcare costs. To watch this video visit here:  https://www.lifesciencemarketresearch.com/videos/signature-series-scaling-robotics-beyond-singularly-focused-procedures-to-combat-scarcity-and-rising-cost-lsi-usa-25

May was another impressive month of funding for the LSI Alumni, raising over $120 million in new capital across 13 new deals. Our monthly Alumni Funding Update features transactions made by these medical device startups and their investors, as well as links to our proprietary media and coverage of the companies themselves. Companies featured in the May 2025 update include: Accelus Obtained new growth funding led by Concord Health Partners to drive commercial scaling and advance the development of its expandable spinal implant portfolio. The company also named seasoned medtech executive Bernie Haffey as Chairman of the Board to help steer its next stage of strategic expansion. Cosm Medical Completed the initial tranche of its Seed Extension round to fast-track commercialization of its personalized, AI-enabled 3D-printed pelvic health solutions. The funding will support post-FDA clearance growth and upcoming clinical presentations at IUGA and other major U.S. women’s health conferences. ...

In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni secure over $63M in new funds, receive FDA 510(k) clearances, announce an acquisition, and much more as we wind down   LSI Asia  ’25 in Singapore and gear up for  LSI Europe  ’25 in London (September 7–11). Accelus Received FDA 510(k) clearance for the FlareHawk Interbody Fusion System to be safely subjected to MRI scanning in certain conditions. The clearance supports Accelus’s commitment to safe, high-performance spinal solutions and expands imaging options for patients with FlareHawk implants. Aortyx Raised $16M to advance its bioresorbable aortic patch toward first-in-human trials. The funding supports continued development of Aortyx’s minimally invasive, tissue-regenerating solution for aortic dissection and positions the company for clinical entry within two years. Atraverse Medical Closed $29.4M in follow-on financing to scale U.S. commercialization of HOTW...

Every week, LSI’s Market Intelligence team dives into a different topic shaping the future of medical technology. From disruptive startups to fast-growing device segments, we connect the dots between clinical demand, market dynamics, and innovation pipelines. Here’s what the LSI Market Intelligence team tracked this past month across electrophysiology (EP), transcatheter mitral valve replacement (TMVR), and the U.S. and APAC medtech markets. To read more about visit here:  https://www.slideserve.com/George125/medtech-pulse-check-by-the-numbers  

The global rise of end-stage kidney disease (ESKD) highlights a longstanding truth: while dialysis is life-saving, it remains a costly, labor-intensive, and outdated solution. In an era marked by aging populations and chronic disease, the urgency to modernize how we manage kidney failure is only growing. To read more about visit here:  https://www.slideshare.net/slideshow/inside-the-dialysis-market-growth-gaps-and-what-s-next/280697357

In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni enter new partnerships, secure new funds, achieve regulatory milestones, and much more on the road to LSI Asia ’25 in Singapore (June 10–13). 3DBioFibR Raised $3M in equity financing to expand manufacturing capacity, pursue ISO 13485 certification, and support commercial growth of its advanced biopolymer fiber platform. The investment enables 3DBioFibR to meet growing demand across medical, defense, and consumer sectors with high-performance, clinically relevant biomaterials. AliveCor Announced a year-long partnership with the British Heart Foundation to support cardiovascular research through cause-related donations tied to KardiaMobileⓇ 6L sales in the UK. The campaign unites AliveCor’s AI-powered ECG technology with the charity’s legacy in scientific research to advance early detection and treatment of heart conditions. BiVACOR Received FDA Breakthrough Device Designation for its...

Under the direction of co-founders Dr. Lara Zibners and Thang Vo-Ta, Calla Lily Clinical Care is reimagining vaginal drug delivery with its CallavidⓇ device — engineering a next-generation platform that improves both clinical outcomes and patient experience in women’s health. “Our revolutionary Callavid platform hugely increases the possibilities for intravaginal drug delivery by enabling treatments with enhanced efficacy, lower drug doses, and minimized side effects,” said Vo-Ta. With its pioneering drug-device combination product, NIHR-funded clinical trial shortly underway, and a platform approach initially addressing miscarriage, IVF, and vaginal microbiome disorders, Calla Lily is redefining what it means to put women’s needs first in medical innovation. Origin Story The idea for Calla Lily Clinical Care was born from personal experience. Dr. Lara Zibners, a board-certified pediatrician and emergency medicine specialist, had gone through seven rounds of IVF — all of which had fail...

Big deals, even bigger questions. Jonathan Norris of HSBC Innovation Banking explains why 2025 is already one for the books. Venture investment across the medical device sector kicked off 2025 with a bang, posting $2.6 billion in first-quarter funding across 132 deals — the highest quarterly dollar mark in three years. According to  Jonathan Norris , Managing Director at  HSBC Innovation Banking , who writes comprehensive reports on the venture healthcare ecosystem, this surge marks a 20% rise in both capital and deal count compared to the 2024 average. “Not only did we have more dollars, but there were more deals, which is really good to see,” Norris says, in a recent interview with  The Lens . “I think the quick and easy takeaway is that more companies were getting funded in Q1, and a good percentage of the bigger deals in the quarter were PMA pivotal trial rounds. It looks like positive momentum for the sector to see a big quarter. That’s our 35,000-foot view.” But ben...